Sun Pharma's Fibromun Fails to Meet PFS Endpoint in Soft Tissue Sarcoma, but Shows Promise in Glioblastoma and Skin Cancers

Sun Pharmaceutical Industries Limited has released updates on Fibromun and Nidlegy. The Phase II FLASH study of Fibromun in last-line soft tissue sarcoma did not meet its primary endpoint for Progression Free Survival (PFS). However, in GLIOSTAR, an improvement in survival was observed in the subgroup of patients with limited exposure to alkylating agents. The GLIOSTUN clinical trial has completed patient enrollment in the United States and is expected to report survival data in September 2026. A new Phase III registrational study (FIBROSARC-2) is planned for Fibromun, with overall survival as the primary endpoint. Nidlegy, a biopharmaceutical product developed for the treatment of skin cancers, is preparing a new submission in Europe and a Phase III clinical trial in locally advanced melanoma is ongoing in the United States.